Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.

NCT ID: NCT00279721

Last Updated: 2012-01-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-01-31
• Study Completion Date: 2010-06-30

Brief Summary

Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

Detailed Description

Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

Conditions

Thyroid Neoplasms

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

IMRT

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• resected well-differentiated throid cancer with at least one high risk feature for locoregional recurrence

Exclusion Criteria

• medullary or anaplastic thyroid cancer, unresectable

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Alberta Health services

OTHER

Sponsor Role: lead

Principal Investigators

Harold Lau, MD

Role: PRINCIPAL_INVESTIGATOR

Tom Baker Cancer Centre

Other Identifiers

18916

Identifier Type: -

Identifier Source: org_study_id